iTeos Therapeutics targets the tumor microenvironment to boost immune cell efficiency in cancer eradication.

Immunotherapy is a revolutionary approach to cancer treatment that aims to educate the immune system to recognize and eliminate the tumor. iTeos Therapeutics leverages its expertise in tumor immunology, translational medicine and drug discovery to design the next wave of immunotherapies.

Based on the pioneering work of Ludwig Cancer Research (LICR) and the de Duve Institute (UCLouvain, Belgium), iTeos aims to unlock the full potential of immunotherapy by improving the frequency, depth and duration of immunotherapy. the answer and extending the therapeutic benefits to more patients.

iTeos has a broad portfolio of projects focused on multiple complementary mechanisms of action, including small molecule antagonists targeting the A2A receptor as well as antibodies against TIGIT.